{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:44:31Z","timestamp":1790405071791,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2021,10]]},"abstract":"Abstract<\/jats:title>\n \n Aim<\/jats:title>\n To confirm the efficacy and safety of dasiglucagon when administered via an autoinjector device.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods<\/jats:title>\n In this double\u2010blind trial, 45 participants with type 1 diabetes were randomized 3:1 to receive a single subcutaneous dose of dasiglucagon 0.6\u00a0mg or placebo following controlled induction of hypoglycaemia. The primary endpoint was time to plasma glucose recovery, defined as a plasma glucose increase of 20\u2009mg\/dL or higher from baseline without rescue intravenous glucose.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Median (95% CI) observed time to recovery was 10.0 (8.0; 12.0) minutes for dasiglucagon and 35.0 (20.0; \u2212) minutes for placebo (\n P<\/jats:italic>\n \u2009<\u2009.001). Plasma glucose recovery was achieved within 15\u2009minutes by 88% of participants receiving dasiglucagon versus none receiving placebo (\n P<\/jats:italic>\n \u2009<\u2009.01). Site of injection (buttock or deltoid) was not shown to have any effect on time to recovery (\n P<\/jats:italic>\n \u00a0=\u00a0.84). No serious adverse events occurred. As expected for glucagon treatment, nausea and vomiting were common adverse events in dasiglucagon\u2010treated participants.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Dasiglucagon provided rapid reversal of hypoglycaemia in adults with type 1 diabetes. Dasiglucagon administration was well tolerated. The aqueous formulation of dasiglucagon in a ready\u2010to\u2010use autoinjector device that can be carried at room temperature may provide a reliable treatment for severe hypoglycaemia.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.14475","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:31:07Z","timestamp":1624581067000},"page":"2329-2335","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Dasiglucagon, a next\u2010generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double\u2010blind trial"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-3462","authenticated-orcid":false,"given":"Timothy S.","family":"Bailey","sequence":"first","affiliation":[{"name":"AMCR Institute Escondido California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Willard","sequence":"additional","affiliation":[{"name":"ProSciento San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie J.","family":"Klaff","sequence":"additional","affiliation":[{"name":"Rainier Clinical Research Center Renton Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenine","family":"Yager Stone","sequence":"additional","affiliation":[{"name":"AMCR Institute Escondido California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Melgaard","sequence":"additional","affiliation":[{"name":"Zealand Pharma A\/S S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Tehranchi","sequence":"additional","affiliation":[{"name":"Zealand Pharma A\/S S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12698"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S20633"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-S006"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd20-as01"},{"issue":"1","key":"e_1_2_9_6_1","first-page":"4","article-title":"Glucagon administration \u2013 underevaluated and undertaught","volume":"18","author":"Harris GDA","year":"2001","journal-title":"Pract Diabetes Int."},{"key":"e_1_2_9_7_1","first-page":"45","article-title":"Nasal glucagon: a new way to treat severe hypoglycemia in patients with diabetes","volume":"18","author":"Pietrzak I","year":"2020","journal-title":"Pediatr Endocrinol Diabetes Metab."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd19-0040"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi061228n"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2995"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2480"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-0822-9"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.796"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1402"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2019-0502"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0148"},{"key":"e_1_2_9_17_1","unstructured":"Gvoke Summary Basis of Approval.Application Number 212097 FDA Application Review Files Clinical Review (FDA homepage)."},{"key":"e_1_2_9_18_1","unstructured":"Baqsimi Summary Basis of Approval.Application Number 210134 FDA Application Review Files Clinical Review (FDA homepage)."}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14475","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:34:09Z","timestamp":1761885249000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/dom.14475"],"URL":"https:\/\/doi.org\/10.1111\/dom.14475","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"assertion":[{"value":"2021-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}